Frost & Sullivan: U.S. Nuclear Medicine and PET Imaging Systems Market Witnessed a Rebound in 2010, With PET Blazing the Trail
MOUNTAIN VIEW, California, March 29, 2012 /PRNewswire/ --
- Trend toward personalized medicine uplifts market prospects
After witnessing a downtrend for several years, revenues in the U.S. nuclear medicine and positron emission tomography (PET) imaging systems market finally pivoted in 2010. New radiotracers and technologies are expanding the clinical scope and customer base of nuclear medicine and PET imaging. As a result, declines in retrenching areas of the market are poised to be offset by strong growth in emerging end-user market segments.
Nuclear medicine and PET are molecular imaging modalities, providing data pertaining to molecular alterations, which are the origin of disease. In contrast, classical imaging modalities, such as X-ray, reveal only the changes in anatomy, which are essentially the end effects of disease and its associated molecular alterations.
New analysis from Frost & Sullivan's (http://www.medicalimaging.frost.com) U.S. Nuclear Medicine and PET Imaging Systems Market research finds that the market earned revenues of $552.4 million in 2010 and estimates this figure to reach $841.8 million in 2017.
If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at firstname.lastname@example.org, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
"The unique ability of nuclear medicine and PET to enable characterization of biological processes at the cellular and molecular levels is bringing increasing attention to these imaging modalities as medicine evolves toward more personalized forms of treatment," said Frost & Sullivan Industry Analyst Roberto G. Aranibar. "This powerful capability of nuclear medicine and PET will become increasingly relevant as personalized healthcare becomes mainstream practice in modern medicine."
Recognizing this advantage, industry participants are gravitating toward this area of imaging. As a result, nuclear medicine and PET imaging systems market revenues experienced a growth upsurge in 2010, and they are expected to continue growing for the next several years.
Molecular imaging has been a key enabling factor for treatment that is selected according to a patient's unique disease state. For example, in cancer treatments, numerous chemotherapy options are available, and a patient's response to a particular treatment can vary considerably based on the specific molecular characteristics of the cancer. With molecular imaging, however, clinicians can determine which characteristics are present in a cancer and use this information to make the most appropriate treatment decision on a patient-by-patient basis.
Ongoing challenges surrounding the state of the economy as well as changes in healthcare policy and reimbursement are forcing more private practice physicians and independent imaging centers to opt for affiliation with larger provider organizations. This shift in the healthcare provider landscape has led to rapidly diminishing revenues within the private practice cardiology market, which formerly accounted for a significant proportion of revenues in the more mature and established nuclear medicine segment of the market.
Naturally, the evolving healthcare provider landscape has led to changes in the types of imaging systems that are being demanded in the marketplace. For example, the need for dedicated cardiac scanners appears to be diminishing, as more cardiologists become affiliated with larger institutions that often benefit more from general-purpose scanners with a broader scope of clinical application.
"Nuclear medicine imaging equipment manufacturers that previously offered only dedicated cardiac scanners have reacted to changes in the healthcare provider landscape by further diversifying their product portfolios in order to include clinically versatile, general-purpose gamma camera systems," said Aranibar. "A number of manufacturers have also chosen to focus on other niche, yet emerging, applications of nuclear medicine and PET that involve molecular breast imaging and brain imaging."
U.S. Nuclear Medicine and PET Imaging Systems Market is part of the Advanced Medical Technologies Growth Partnership Service program, which also includes research in the following markets: North American Market for Computer-aided Detection and Diagnosis, U.S. Preclinical Small Animal Imaging Markets, and North American Advanced 3-D/4-D Visualization and Clinical Applications for Medical Imaging Markets. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
U.S. Nuclear Medicine and PET Imaging Systems Market
Corporate Communications - North America
SOURCE Frost & Sullivan
More by this Source
Frost & Sullivan: Australian Online General Advertising Market to reach A$2.43 billion by 2018
27 Nov, 2014, 07:23 GMT
Frost & Sullivan: APAC Healthcare Providers Leverage IT to Boost Customer Experience
27 Nov, 2014, 07:03 GMT
Get content for your website
Enhance your website's or blog's content with PR Newswire's customised real-time news feeds.
Contact PR Newswire
Send us an email at MarketingUK@prnewswire.co.uk or call us at +44 (0)20 7454 5382
Become a PR Newswire client
Request more information about PR Newswire products & services or call us at +44 (0)20 7454 5382